Skip to main content

Table 1 Patient characteristics

From: Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer — a retrospective comparative study with PET/CT and breast MRI

Characteristics

PET/CT a

N = 275

(244 with MRI,

31 PET/CT alone)

MRIb

N = 244

(with PET/CT)

p-value

Age, years (mean ± SD)

57.5 ± 12.8

56.7 ± 12.5

0.71

Location, N(%)

  

0.99

 Right

127 (46.2)

112 (45.9)

 

 Left

148 (53.8)

132 (54.1)

 

Tumor size on MRI, cm (mean ± SD)

3.5 ± 1.8

3.5 ± 1.8

-

ALN positive in PET report, N(%)

  

-

 Yes

86 (31.3)

-

 

 No

189 (68.7)

-

 

ALN positive in MRI report, N(%)

NA = 31

 

-

 Yes

115 (47.1)

115 (47.1)

 

 No

129 (52.9)

129 (52.9)

 

Low-burden positive ALN, N(%)

  

0.85

 1 Lymph node

41 (14.9)

40 (16.4)

 

 2 Lymph nodes

23 (8.4)

20 (8.2)

 

Breast surgery, N(%)

  

0.78

 E-BCS

31 (11.3)

31 (12.7)

 

 E-NSM/SSM

14 (5.1)

14 (5.7)

 

 R-NSM

15 (5.5)

15 (6.2)

 

 C-BCS

98 (35.6)

94 (38.5)

 

 C-TM/SSM/NSM

117 (42.6)

90 (36.9)

 

Axillary surgery, N(%)

  

0.69

 SLNB

164 (59.6)

163 (66.8)

 

 SLNB + ALND

40 (14.6)

40 (16.5)

 

 ALND

71 (25.8)

39 (16.1)

 

Number of harvested ALNs (mean ± SD)

6.5 ± 6.4

6.3 ± 6.3

0.94

Number of metastatic ALNs (mean ± SD)

1.4 ± 3.2

1.3 ± 3.3

0.75

Pathologic T stage, N(%) (NA = 8)

  

0.99

 Tis

6 (2.3)

6 (2.6)

 

 T1

93 (34.8)

84 (35.4)

 

 T2

137 (51.3)

123 (51.9)

 

 T3

26 (9.7)

20 (8.4)

 

 T4

5 (1.9)

4 (1.7)

 

Pathologic N stage, N(%)

  

0.88

 N0

162 (58.9)

149 (61)

 

 N1mi

10 (3.6)

10 (4.1)

 

 N1

72 (26.2)

62 (25.4)

 

 N2

22 (8)

15 (6.2)

 

 N3

9 (3.3)

8 (3.3)

 

Pathologic stage, N(%) (NA = 8)

  

0.94

 0

4 (1.5)

4 (1.6)

 

 I

58 (21.1)

53 (21.7)

 

 II

158 (57.5)

142 (58.2)

 

 III

36 (13.5)

32 (13.1)

 

 IV

11 (4.1)

6 (2.4)

 

Histological type, N(%)

  

0.99

 DCIS

6 (2.2)

6 (2.4)

 

 IDC

232 (84.3)

206 (84.4)

 

 ILC

18 (6.6)

16 (6.6)

 

 Othersc

19 (6.9)

16 (6.6)

 

Grade, N(%) (NA = 10)

  

0.99

 I

52 (19.6)

47 (20)

 

 II

144 (54.3)

125 (53.2)

 

 III

69 (26.1)

63 (26.8)

 

Molecular subtype, N(%) (NA = 23)

  

0.93

 Luminal A

92 (36.6)

83 (36.2)

 

 Luminal B1

67 (26.6)

62 (27.1)

 

 Luminal B2

36 (14.2)

34 (14.9)

 

 HER-2

31 (12.3)

27 (11.8)

 

 Triple negative

26 (10.3)

23 (10)

 
  1. MRI magnetic resonance imaging, ALN axillary lymph node, E-BCS endoscopic-assisted breast conserving surgery, E-NSM/SSM endoscopic-assisted nipple/skin-sparing mastectomy, R-NSM robotic-assisted nipple-sparing mastectomy, C-BCS conventional breast-conserving surgery, C-TM/SSM/NSM conventional total mastectomy and nipple-/skin-sparing mastectomy, SLNB sentinel lymph node biopsy, SLNB + ALND sentinel lymph node biopsy followed by axillary lymph node dissection in the same operation, ALND axillary lymph node dissection, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NA not analyzed
  2. aOf 275 patients who underwent preoperative PET/CT, 31 of them underwent PET/CT only, and the other 244 patients also received preoperative MRI
  3. bAll 244 patients who received preoperative MRI also underwent preoperative PET/CT
  4. cOther pathology includes mucinous carcinoma, papillary carcinoma, metaplastic carcinoma, apocrine carcinoma, neuroendocrine carcinoma
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us